Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

1.6K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.6K
Pneumothorax-I01:26

Pneumothorax-I

710
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
710
Pneumonia IV: Management01:28

Pneumonia IV: Management

553
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
553
Endocarditis IV: Nursing Management01:29

Endocarditis IV: Nursing Management

121
Infective endocarditis (IE) is a chronic infection of the heart's endocardium, primarily affecting the heart valves. A detailed nursing assessment for a patient with IE involves collecting subjective and objective data to ensure an accurate diagnosis and timely intervention.Subjective DataThe nurse gathers information about the patient's symptoms and complaints during the subjective assessment. Patients with infective endocarditis often report non-specific symptoms that can mimic other...
121
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

4.2K
Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
4.2K
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

74
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
74

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection.

The Journal of antimicrobial chemotherapy·2026
Same author

Dengue and chikungunya vaccination in military populations, a comment on Bogacka et al.

Travel medicine and infectious disease·2026
Same author

Cutaneous mucormycosis confirmed using a <i>Mucorales</i>-specific monoclonal antibody: a case study.

Frontiers in medicine·2026
Same author

Ophthalmic features of HIV associated cryptococcal meningitis in Malawian Adults: an observational study.

Wellcome open research·2026
Same author

Design and feasibility considerations for a phase 3 efficacy trial of the M72/AS01<sub>E-4</sub> tuberculosis vaccine.

Vaccine·2026
Same author

Evaluation of long-term consequences among snakebite survivors in rural Kenya including validation of a functional limitations assessment tool.

PLoS neglected tropical diseases·2026
Same journal

Expert consensus on case definitions in human loiasis: a Delphi study.

The Lancet. Infectious diseases·2026
Same journal

The Bundibugyo virus disease outbreak: a warning signal for risks to health workers.

The Lancet. Infectious diseases·2026
Same journal

Trials of medical countermeasures to begin in DR Congo.

The Lancet. Infectious diseases·2026
Same journal

Community-based tuberculosis screening with computer-aided detection technology alone and in combination with point-of-care C-reactive protein testing: a paired screen-positive trial.

The Lancet. Infectious diseases·2026
Same journal

Context matters: WHO-recommended tools in combinations validated for community tuberculosis screening.

The Lancet. Infectious diseases·2026
Same journal

Global, regional, and national burden of tuberculosis and multidrug-resistant tuberculosis by HIV status, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.

The Lancet. Infectious diseases·2026
See all related articles

Related Experiment Video

Updated: Nov 8, 2025

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

12.1K

Cryptococcal meningoencephalitis: time for action.

Katharine Elizabeth Stott1, Angela Loyse2, Joe N Jarvis3

  • 1Antimicrobial Pharmacodynamics and Therapeutics, Institute of Translational Medicine, University of Liverpool, Liverpool Health Partners, Liverpool, UK; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi.

The Lancet. Infectious Diseases
|April 19, 2021
PubMed
Summary
This summary is machine-generated.

Cryptococcal meningoencephalitis, a fungal infection, causes high mortality, especially in people with HIV in low-income countries. Improved interventions and implementation science are crucial to reduce preventable deaths from this infection.

More Related Videos

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

634
Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

7.4K

Related Experiment Videos

Last Updated: Nov 8, 2025

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
09:57

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

12.1K
Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

634
Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

7.4K

Area of Science:

  • Infectious Diseases
  • Mycology
  • Public Health

Background:

  • Cryptococcal meningoencephalitis is a significant cause of mortality and morbidity globally.
  • The highest burden of this fungal infection is observed in individuals living with HIV in low- and middle-income countries.
  • Despite being preventable and treatable, high death rates persist.

Purpose of the Study:

  • To review the causes of excessive mortality associated with cryptococcal meningoencephalitis.
  • To summarize interventions demonstrating a survival benefit.
  • To identify knowledge and practice gaps contributing to the ongoing high death toll.

Main Methods:

  • This review synthesizes existing literature and clinical trial data on cryptococcal meningoencephalitis.
  • It focuses on mortality causes, effective interventions, and implementation science challenges.
  • Analysis includes data from clinical trials of antifungal induction regimens.

Main Results:

  • Even with optimal antifungal induction (amphotericin B deoxycholate and flucytosine), 10-week mortality in a clinical trial setting was 24% for people with HIV.
  • Significant gaps in knowledge and practice contribute to the persistent high mortality.
  • The review highlights the need for increased scope of interventional programs.

Conclusions:

  • Cryptococcal meningoencephalitis remains a critical global health challenge, particularly for immunocompromised populations.
  • There is an urgent need for expanded interventional programs and country-specific implementation science.
  • Addressing knowledge gaps and improving practices are essential to reduce the excessive mortality from this fungal infection.